Sat, Sep 20, 2014, 5:17 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

CR Bard Inc. Message Board

  • annamcallan annamcallan Jan 28, 2010 3:36 PM Flag

    Urology segment

    A small product Contigen in the urology segment will disappear in 18 months because Allergan the supplier of the collagen is shutting down production. Why not qualify a new supplier? Is the brand so small that it is not worth the expense of qualifying a new supplier?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This product was innovative years ago when it came out: biomaterial, non-invasive, and easy to administer. It is temporary b/c the collagen is absorbed and you need to get repeated injections. Bard thought the re-occuring revenue would be a windfall, patients thought otherwise. So... they bought a start up years ago (1997) which would be a permanent solution. They did nothing with it. Why? That is what I want to know? As for a new supplier of collagen, yes very possible.

 
BCR
147.23+0.35(+0.24%)Sep 19 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.